Severe myoclonic epilepsy of infancy (SMEI) is a complex form of epilepsy that was first
described in France in 1978. Because the myoclonic component of this epilepsy is not�…

Dravet syndrome was described in 1978 by Dravet (1978) under the name of severe
myoclonic epilepsy in infancy (SMEI). The characteristics of the syndrome were confirmed�…

Few studies focused on the long‐term outcome of Dravet syndrome in adulthood are
available in the literature, but all are concordant. In this article, we consider the outcomes of�…

Purpose: To clarify the role of epilepsy and genetic background in determining the cognitive
outcome of patients with Dravet syndrome. Methods: In this retrospective study, we reviewed�…

In order to assess the cognitive and adaptive profiles of school-aged patients with Dravet
syndrome (DS), we proposed to evaluate the intelligence and adaptive scores in twenty-one�…

In this issue of Brain, Brunklaus et al. report a study of 241 patients with Dravet syndrome
carrying a SCN1A mutation, with the aim of identifying predictors of developmental outcome�…

Severe myoclonic epilepsy in infancy (SME) was described by Dravet in 1978 (1). In 1992,
there were at least 192 published cases (2). At present, it is more difficult to give a precise�…

Dravet syndrome is not one of the most frequent severe epilepsies affecting infants during
the first year of life. In the most recent epidemiological study, in Sweden, its estimated�…

To describe the outcome of Dravet syndrome (DS) in adolescents and adults we conducted
a longitudinal retrospective study of two independent cohorts of 34 adolescents (group 1)�…

Severe myoclonic epilepsy in infancy (SMEI) is a rare disease, characterized by febrile and
afebrile, generalized and unilateral, clonic or tonic–clonic seizures that occur in the first year�…